PainCeptor Pharma is a private Canadian company focused on the development of drugs that act outside the central nervous system to treat pain.^[1] The company's strategic focus on peripheral rather than central acting therapeutics is an attempt to avoid the known side-effects of existing central acting agents.^[2] The primary molecular targets addressed by PainCeptor are members of the ASIC ion channel family and nerve growth factor (NGF) and NGF receptors.^[2] Though PainCeptor refers to itself as a biopharmaceutical company on its website,^[1] its two primary publicly reported drug discovery projects aim to deliver small molecule therapeutics.^[2]

References

1. ^ ^{a b} PainCeptor Pharma corporate home page (HTML). PainCeptor Pharma public corporate website. Retrieved on 2007-10-18.
2. ^ ^{a b c} Dimond, Patricia F.. "Revamping Drug Discovery Strategies", Drug Discovery, Genetic Engineering News, 2007-10-01. Retrieved on 2007-10-18.